Template:Crofab dosing: Difference between revisions

 
(4 intermediate revisions by one other user not shown)
Line 1: Line 1:
===Initial Administration===
===Initial Administration===
*Initial dose: 6 vials in 250 mL normal saline<ref>Gerardo CJ. The efficacy of crotalidea polyvalent immune fab (ovine) antivenom versus placebo plus optional rescue therapy on recovery from copperhead snake envenomation: A randomized, double-blind, placebo-controlled, clinical trial. Annals of EM. August 2017. 70(2):233-244.</ref>
*Initial dose: 6 vials<ref>Gerardo CJ. The efficacy of crotalidea polyvalent immune fab (ovine) antivenom versus placebo plus optional rescue therapy on recovery from copperhead snake envenomation: A randomized, double-blind, placebo-controlled, clinical trial. Annals of EM. August 2017. 70(2):233-244.</ref>
**May repeat dose in 2 hours if symptoms not controlled
*Typically diluted into 250 cc or 1 L of normal saline and infused over an hour
*Typically diluted into 250 cc or 1 L of normal saline and infused over an hour.
*Same dose for both adults and pediatrics (may have to adjust the dilution of CroFab for small children so that they are not volume overloaded)
*Same dose for both adults and pediatrics (may have to adjust the dilution of CroFab for small children so that they are not volume overloaded)


===Maintenance therapy===
===Maintenance therapy===
*Infuse 2-vial doses at 6, 12, and 18hr after initial control achieved
*May repeat dose (2 vials) at 6, 12, and 18 hours later if symptoms not controlled<ref>Gerardo CJ. The efficacy of crotalidea polyvalent immune fab (ovine) antivenom versus placebo plus optional rescue therapy on recovery from copperhead snake envenomation: A randomized, double-blind, placebo-controlled, clinical trial. Annals of EM. August 2017. 70(2):233-244.</ref>
*''Maintance therapy may be indicated after initial dosing based on local protocols even if control is achieved.<ref>Crofab treatment agorithmn http://www.crofab.com/documents/CroFab-Treatment_Algorithm.pdf</ref>
**''Maintance therapy may be indicated after initial dosing based on local protocols even if control is achieved.<ref>Crofab treatment agorithmn http://www.crofab.com/documents/CroFab-Treatment_Algorithm.pdf</ref>


===Envenomation control measurement===
===Envenomation control measurement===
Line 16: Line 15:


===Side Effects===
===Side Effects===
*Acute allergic reactions occur in <10% pts
*Acute [[allergic reactions]] occur in <10% pts
**If occurs stop infusion and give epinephrine/antihistamines if needed
**If occurs stop infusion and give epinephrine/antihistamines if needed
*Recurrent [[thrombocytopenia]] has been described up to 2 weeks after transfusion with FabAV and is likely a result of isolated renal clearance of FabAV and persistent presence of actual venom in serum.<ref>Ruha AM et al. Late hematologic toxicity following treatment of rattlesnake envenomation with crotalidae polyvalent immune Fab antivenom. Toxicon. 2011;57:53–59.</ref>
*Recurrent [[thrombocytopenia]] has been described up to 2 weeks after transfusion with FabAV and is likely a result of isolated renal clearance of FabAV and persistent presence of actual venom in serum.<ref>Ruha AM et al. Late hematologic toxicity following treatment of rattlesnake envenomation with crotalidae polyvalent immune Fab antivenom. Toxicon. 2011;57:53–59.</ref>
**Warrants close monitoring of platelets by primary physician or return visit after discharge
**Warrants close monitoring of platelets by primary physician or return visit after discharge
*[[Serum sickness]] is unlikely but precautions should be given to patents upon discharge
*[[Serum sickness]] is unlikely but precautions should be given to patents upon discharge

Latest revision as of 17:26, 28 September 2019

Initial Administration

  • Initial dose: 6 vials[1]
  • Typically diluted into 250 cc or 1 L of normal saline and infused over an hour
  • Same dose for both adults and pediatrics (may have to adjust the dilution of CroFab for small children so that they are not volume overloaded)

Maintenance therapy

  • May repeat dose (2 vials) at 6, 12, and 18 hours later if symptoms not controlled[2]
    • Maintance therapy may be indicated after initial dosing based on local protocols even if control is achieved.[3]

Envenomation control measurement

  • Observe for progression of envenomation during and after antivenom infusion
  • Measure limb circumference at several sites above and below bite
  • Mark advancing border of edema q30min
  • Repeat labs q4hr or after each course of antivenom (whichever is more frequent)

Side Effects

  • Acute allergic reactions occur in <10% pts
    • If occurs stop infusion and give epinephrine/antihistamines if needed
  • Recurrent thrombocytopenia has been described up to 2 weeks after transfusion with FabAV and is likely a result of isolated renal clearance of FabAV and persistent presence of actual venom in serum.[4]
    • Warrants close monitoring of platelets by primary physician or return visit after discharge
  • Serum sickness is unlikely but precautions should be given to patents upon discharge
  1. Gerardo CJ. The efficacy of crotalidea polyvalent immune fab (ovine) antivenom versus placebo plus optional rescue therapy on recovery from copperhead snake envenomation: A randomized, double-blind, placebo-controlled, clinical trial. Annals of EM. August 2017. 70(2):233-244.
  2. Gerardo CJ. The efficacy of crotalidea polyvalent immune fab (ovine) antivenom versus placebo plus optional rescue therapy on recovery from copperhead snake envenomation: A randomized, double-blind, placebo-controlled, clinical trial. Annals of EM. August 2017. 70(2):233-244.
  3. Crofab treatment agorithmn http://www.crofab.com/documents/CroFab-Treatment_Algorithm.pdf
  4. Ruha AM et al. Late hematologic toxicity following treatment of rattlesnake envenomation with crotalidae polyvalent immune Fab antivenom. Toxicon. 2011;57:53–59.